Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Anticancer Res ; 38(3): 1585-1593, 2018 03.
Article in English | MEDLINE | ID: mdl-29491089

ABSTRACT

BACKGROUND/AIM: In this retrospective study, we compared breast cancer patients treated with and without mistletoe lectin I (ML-I) in addition to standard breast cancer treatment in order to determine a possible effect of this complementary treatment. PATIENTS AND METHODS: This study included 18,528 patients with invasive breast cancer. Data on additional ML-I treatments were reported for 164 patients. We developed a "similar case" method with a distance measure retrieved from the beta variable in Cox regression to compare these patients, after stage adjustment, with their non-ML-1 treated counterparts in order to answer three hypotheses concerning overall survival, recurrence free survival and life quality. RESULTS: Raw data analysis of an additional ML-I treatment yielded a worse outcome (p=0.02) for patients with ML treatment, possibly due to a bias inherent in the ML-I-treated patients. Using the "similar case" method (a case-based reasoning approach) we could not confirm this harm for patients using ML-I. Analysis of life quality data did not demonstrate reliable differences between patients treated with ML-I treatment and those without proven ML-I treatment. CONCLUSION: Based on a "similar case" model we did not observe any differences in the overall survival (OS), recurrence-free survival (RFS), and quality of life data between breast cancer patients with standard treatment and those who in addition to standard treatment received ML-I treatment.


Subject(s)
Breast Neoplasms/drug therapy , Ribosome Inactivating Proteins, Type 2/therapeutic use , Toxins, Biological/therapeutic use , Aged , Breast Neoplasms/pathology , Disease-Free Survival , Humans , Middle Aged , Neoplasm Invasiveness , Quality of Life , Retrospective Studies , Treatment Outcome
2.
Anticancer Res ; 36(8): 3855-63, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27466487

ABSTRACT

BACKGROUND: The receptors for estrogen (ESR1) and progesterone (PGR) are both part of the same signaling pathway and routinely used for breast cancer stratification. We tested the hypothesis if a coordinated analysis could add extra information for prognostic stratification. MATERIALS AND METHODS: ESR1 and PGR gene expression was first investigated by quantitative reverse transcription polymerase chain reaction in fresh-frozen invasive ductal breast cancer samples (Hamburg collective, case-control, n=317). Our results were then tested using two datasets generated by different technical approaches: i) a public DNA-chip data set (GSE3494, n=251) and ii) semiquantitative protein expression data based on immunohistochemistry (Stuttgart collective, n=18,528). RESULTS: The PGR/ESR1 gene-expression ratio was a prognostic indicator in those with ESR1/PGR-positive breast cancer (Hamburg collective), with a high PGR/ESR1 expression ratio indicating a favorable outcome. In all three collectives, the PGR/ESR1 mRNA ratio or its protein equivalent was a univariate prognostic factor and also a multivariate prognostic factor in the Hamburg and Stuttgart collectives. CONCLUSION: Calculation of the PGR/ESR1 gene-expression ratio and its immunohistochemical surrogate could be a useful and simple addition to routine breast cancer diagnostics. A high PGR/ESR1 ratio could be indicative of a favorable clinical outcome.


Subject(s)
Biomarkers, Tumor/biosynthesis , Breast Neoplasms/diagnosis , Breast Neoplasms/genetics , Estrogen Receptor alpha/biosynthesis , Receptors, Progesterone/biosynthesis , Aged , Biomarkers, Tumor/genetics , Breast Neoplasms/pathology , Estrogen Receptor alpha/genetics , Estrogens/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Kaplan-Meier Estimate , Middle Aged , Prognosis , Receptors, Progesterone/genetics , Risk Assessment
3.
Anticancer Res ; 34(7): 3647-56, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24982382

ABSTRACT

BACKGROUND: The well-characterized tubular-type of breast tumors is classified as low-risk breast cancer. PATIENTS AND METHODS: We report on the results of a retrospective analysis on clinical and biological features of 248 tubular breast tumors including follow-up and treatment data from two German series of 21,065 breast cancer cases. The majority of tumors were stage I or stage II, ER- and PR-positive and c-erbB2-negative with a 5-year survival-rate of 96.3%. 51.3% of patients received hormonal treatment, 75.5% had post-operative radiotherapy and 11.8% were treated with a chemotherapeutical regimen. CONCLUSION: Our retrospective analysis showed no treatment benefit for either anti-hormonal or chemotherapeutical regimens. Post-operative radiotherapy, however, improved the survival rate of patients with tubular carcinoma (log-rank=5, p=0.025). Our data suggest that post-operative radiotherapy is an important treatment to prolong survival for patients suffering from tubular breast cancer.


Subject(s)
Breast Neoplasms/pathology , Breast Neoplasms/therapy , Adult , Aged , Cohort Studies , Female , Humans , Middle Aged , Retrospective Studies
4.
Anticancer Res ; 33(4): 1609-19, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23564805

ABSTRACT

BACKGROUND/AIM: We report on survival data of 595 patients with stage I-III lung cancer with respect to TNM classification. MATERIALS AND METHODS: We constructed a basic model consisting of stage and grade, and assessed the improvement of survival prediction after adding comorbidity data, spirometric data, clinical and laboratory parameters. RESULTS: Body mass index (BMI) and presence of a cardiac disease reached statistical significance for prediction of overall survival in a Cox regression model. In addition to BMI (<25 kg/m(2)) and the presence of cardiovascular disease, the spirometric variable (FEV1) predicted early death (less than five months postoperatively). When the survival random forest method was employed to predict disease outcome, creatinine levels and VO2 max became additional variables of interest for predicting survival. CONCLUSION: We propose that our lung cancer database may help to identify variables (aside from histomorphological variables) that are suitable for identifying patients at risk of death after surgical treatment of lung cancer.


Subject(s)
Carcinoma, Non-Small-Cell Lung/mortality , Lung Neoplasms/mortality , Postoperative Complications , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adenocarcinoma, Bronchiolo-Alveolar/mortality , Adenocarcinoma, Bronchiolo-Alveolar/pathology , Adenocarcinoma, Bronchiolo-Alveolar/surgery , Adult , Aged , Aged, 80 and over , Body Mass Index , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Cardiovascular Diseases/etiology , Comorbidity , Creatinine/metabolism , Female , Humans , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Male , Middle Aged , Neoplasm Staging , Oxygen/metabolism , Prognosis , Proportional Hazards Models , Risk Factors , Small Cell Lung Carcinoma/mortality , Small Cell Lung Carcinoma/pathology , Small Cell Lung Carcinoma/surgery , Survival Rate
5.
Z Evid Fortbild Qual Gesundhwes ; 105(5): 365-70, 2011.
Article in German | MEDLINE | ID: mdl-21767795

ABSTRACT

BACKGROUND: Quality-controlled documentation and evaluation of long-term course of disease is essential for measuring the outcome quality in the care of cancer patients. This project, based on the ongoing clinical cancer registry of the Comprehensive Oncology Centre (COC) Stuttgart, was aimed to integrate a long-term follow-up documentation and to compare outcome quality between centres of the OCC. METHODS: In a prospective, non-randomised, multi-centred, registry-based cohort study overall survival, disease free survival and quality of life were evaluated as indicators of outcome quality. The study included all patients suffering from breast, colon or rectum cancer, who were treated with curative intent in one of the centres of the OCC between Sep 30, 2003, and Dec 31, 2008. Cox regressions were used for the statistical evaluation of differences between centres. RESULTS: Patients suffering from breast cancer (n=3,213), colon cancer (n=1,216) and rectum cancer (n=847) were eligible for the analysis. They were treated in 10 of 13 centres of the OCC. Statistically significant differences in the overall survival could be demonstrated between centres. DISCUSSION: This project initiated a regular comparative evaluation of the outcome quality and showed that there are statistically significant differences between centres. Based on these findings, the benchmarking process will have to be further developed and elaborated.


Subject(s)
Benchmarking/standards , Cancer Care Facilities/standards , National Health Programs , Neoplasms/therapy , Outcome Assessment, Health Care/methods , Quality Improvement/standards , Adult , Aged , Breast Neoplasms/diagnosis , Breast Neoplasms/mortality , Breast Neoplasms/therapy , Cohort Studies , Colonic Neoplasms/diagnosis , Colonic Neoplasms/mortality , Colonic Neoplasms/therapy , Disease-Free Survival , Documentation/methods , Female , Germany , Health Services Research , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Neoplasms/diagnosis , Neoplasms/mortality , Outcome Assessment, Health Care/standards , Proportional Hazards Models , Prospective Studies , Quality Indicators, Health Care/standards , Quality of Life , Rectal Neoplasms/diagnosis , Rectal Neoplasms/mortality , Rectal Neoplasms/therapy , Registries
6.
Onkologie ; 30(8-9): 443-9, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17848816

ABSTRACT

BACKGROUND: The homogeneity of the schemes for follow-up care after curative surgical treatment of early breast cancer is still a matter of debate in Germany. We investigated whether symptom-oriented follow-up is equivalent in terms of survival rates to conventional surveillance based on scheduled tests. PATIENTS AND METHODS: In a prospective, non-randomised, multicentre cohort study carried out between 1995 and 2000, 244 patients underwent a conventional follow-up (scheduled laboratory tests including CEA and CA 15-3, chest X-rays and liver ultrasound). 426 patients were monitored in a symptom-oriented manner (additional tests only in the case of symptoms indicating possible recurrence). Mammography, structured histories and physical examinations were done regularly in both branches. 1,108 patients did not participate in the project. They represent 'real world patients', unaffected by the implications of a study. RESULTS: The symptom-oriented follow- up group produced results not inferior to those of the intensive one (p < 0.05) in terms of overall and relapse-free survival. Furthermore, no difference was indicated in terms of overall survival between study participants and the 'real world patients' (p = 0.316). CONCLUSION: The results confirm that regular imaging and laboratory tests have no relevant effect on overall survival of patients after curative primary therapy of early breast cancer and support the implementation of a symptom-oriented routine follow-up.


Subject(s)
Breast Neoplasms/diagnosis , Breast Neoplasms/therapy , Outcome Assessment, Health Care/methods , Risk Assessment/methods , Adult , Breast Neoplasms/epidemiology , Cohort Studies , Female , Follow-Up Studies , Humans , Middle Aged , Prognosis , Reproducibility of Results , Risk Factors , Sensitivity and Specificity , Survival Analysis , Survival Rate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...